Cellectar Posts 46c Per-Share Q3 Loss as Cash Runway Tightens
CLRB sits 17% above its 52-week low of $1.11.
Summary
Cellectar reported a third-quarter loss of 46 cents per share, with the net loss widening to $8.0 million from $6.9 million in Q2. Nine-month cash burn reached $20.3 million, leaving roughly $21 million of liquidity that funds operations only into Q2 2027 without new financing. For a company of this size, that runway gap is the whole story — another raise is the base case, and dilution risk is front and center. The operating narrative still rests on iopofosine I 131, where the September CLOVER WaM subset data in Waldenström's macroglobulinemia was the last positive update, and the company is targeting an FDA filing in 1H 2027.
At the time of this announcement, CLRB was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1M. The 52-week trading range was $1.11 to $4.70. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.